01:50 PM EDT, 06/04/2025 (MT Newswires) -- Moleculin Biotech ( MBRX ) shares dropped about 19% in recent Wednesday trading after the company said no patients achieved complete response in the phase 1b/2 study of Annamycin for the treatment of soft tissue sarcoma lung metastases, a type of cancer.

The trial, however, demonstrated a clinical benefit rate of 59.4%, primarily comprising 18 cases of stable disease and one partial response, the company said.

The median progression-free survival in the 36 subjects participating in the trial was 63 days, while median overall survival clocked in at 411 days, the company said.

In the phase 2 portion of the study, which was made up of 17 subjects, the median progression-free survival was 105 days, with overall survival coming in at 13.5 months, the company added.

Annamycin holds the US Food and Drug Administration's orphan drug designation for the treatment of soft tissue sarcoma.

Price: 0.68, Change: -0.16, Percent Change: -18.55